Cognition Therapeutics Charts New Course for Zervimesine in DLB Psychosis
Cognition Therapeutics has announced a significant development shift in its primary therapeutic candidate, zervimesine. In a recent conference call to discuss the company's Q4 2025 earnings, leadership outlined plans to prioritize the treatment of DLB (dementia with Lewy bodies) psychosis over other neurodegenerative disease indications.
CEO Lisa Ricciardi noted that Cognition has been focused on developing zervimesine for patients with debilitating neurodegenerative diseases since its inception. The company has reported data from phase II studies in dementia with Lewy bodies and mild to moderate Alzheimer's disease, as well as concluded enrollment in an 18-month START trial in early Alzheimer's disease.
However, it is the results of a recent phase II SHIMMER study that have led to this strategic pivot. Dr. Tony Caggiano, Chief Medical Officer, presented findings at the Alzheimer's and Parkinson's Disease Conference in Copenhagen, demonstrating zervimesine's strong impact on neuropsychiatric symptoms, including psychosis. The data showed an 86% slowing of progression relative to placebo, with particularly notable effects on hallucinations and delusions.
Industry experts and regulators have taken notice of this compelling finding. Cognition reported that its type C meeting with the FDA in January was met with enthusiasm for the treatment's potential, and peers during the ADPD meeting were equally impressed. The company is now moving forward to discuss a registrational plan for DLB psychosis with the Division of Psychiatry.
The decision to prioritize DLB psychosis represents a calculated risk that Cognition believes will yield significant benefits. According to Dr. Caggiano, many patients with neurodegenerative diseases experience psychosis, which can have a devastating impact on quality of life. By focusing on this aspect, the company is addressing an area of high unmet medical need.
The path forward is now being shaped by engagement with regulatory bodies and key opinion leaders. Cognition has filed a meeting request with the Division of Psychiatry to outline a registrational plan for zervimesine in DLB psychosis. The outcome will be crucial in determining whether this novel therapy can provide meaningful relief to patients struggling with debilitating symptoms.
